Cargando…

New enzyme-targeting radiosensitizer (KORTUC II) treatment for locally advanced or recurrent breast cancer

Kochi oxydol radiation therapy for unresectable carcinomas II (KORTUC II) is currently the most widely used radiosensitizer in Japan. This sensitizer is a solution consisting of 0.83% sodium hyaluronate and 0.5% hydrogen peroxide. The mixture is injected intratumorally just before radiation therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimbo, Taiju, Nakata, Mio, Yoshioka, Hiroto, Sato, Chikara, Hori, Akihiro, Kimura, Kosei, Iwamoto, Mitsuhiko, Yoshida, Ken, Uesugi, Yasuo, Akiyama, Hironori, Nihei, Keiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506568/
https://www.ncbi.nlm.nih.gov/pubmed/34650808
http://dx.doi.org/10.3892/mco.2021.2388
_version_ 1784581728394805248
author Shimbo, Taiju
Nakata, Mio
Yoshioka, Hiroto
Sato, Chikara
Hori, Akihiro
Kimura, Kosei
Iwamoto, Mitsuhiko
Yoshida, Ken
Uesugi, Yasuo
Akiyama, Hironori
Nihei, Keiji
author_facet Shimbo, Taiju
Nakata, Mio
Yoshioka, Hiroto
Sato, Chikara
Hori, Akihiro
Kimura, Kosei
Iwamoto, Mitsuhiko
Yoshida, Ken
Uesugi, Yasuo
Akiyama, Hironori
Nihei, Keiji
author_sort Shimbo, Taiju
collection PubMed
description Kochi oxydol radiation therapy for unresectable carcinomas II (KORTUC II) is currently the most widely used radiosensitizer in Japan. This sensitizer is a solution consisting of 0.83% sodium hyaluronate and 0.5% hydrogen peroxide. The mixture is injected intratumorally just before radiation therapy (RT) several times. KORTUC II has the effect of neutralizing antioxidant enzymes, while increasing the oxygen tension into the tumor tissue, and achieves marked local effects without notable adverse events. The present report describes cases in which KORTUC II was used to treat patients with locally advanced breast cancer (LABC) or recurrent breast cancer (LRBC). The present study included 30 patients with LABC (n=9) or LRBC (n=21) aimed at local control of tumors, who were followed up for ≥3 months after treatment. The irradiation dose and extent fields were determined by the attending physicians considering various patient factors, such as a performance status, prognosis and presence or absence of adjuvant therapy. The median irradiation dose was 60.4 Gy3.5 (43.6-76.1 Gy3.5) based on the calculation of equivalents of 2 Gy fractions, and the median total number of sensitizer injections was 5 (2-7) times. The median maximum tumor shrinkage was 97.0% and 15 patients (50%) were assessed to have achieved a clinical complete response. The proportion with loco-regional control at 1, 2 and 3 years was 100, 94.7 and 75.4%, respectively, and progression free survival after RT at 1 and 2 years was 59.0 and 24.1%, respectively. KORTUC II exhibited high rates of local tumor control for LABC and LRBC. KORTUC II is expected to be an inexpensive and promising RT method because it is safe and has an excellent radio-sensitizing effect.
format Online
Article
Text
id pubmed-8506568
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-85065682021-10-13 New enzyme-targeting radiosensitizer (KORTUC II) treatment for locally advanced or recurrent breast cancer Shimbo, Taiju Nakata, Mio Yoshioka, Hiroto Sato, Chikara Hori, Akihiro Kimura, Kosei Iwamoto, Mitsuhiko Yoshida, Ken Uesugi, Yasuo Akiyama, Hironori Nihei, Keiji Mol Clin Oncol Articles Kochi oxydol radiation therapy for unresectable carcinomas II (KORTUC II) is currently the most widely used radiosensitizer in Japan. This sensitizer is a solution consisting of 0.83% sodium hyaluronate and 0.5% hydrogen peroxide. The mixture is injected intratumorally just before radiation therapy (RT) several times. KORTUC II has the effect of neutralizing antioxidant enzymes, while increasing the oxygen tension into the tumor tissue, and achieves marked local effects without notable adverse events. The present report describes cases in which KORTUC II was used to treat patients with locally advanced breast cancer (LABC) or recurrent breast cancer (LRBC). The present study included 30 patients with LABC (n=9) or LRBC (n=21) aimed at local control of tumors, who were followed up for ≥3 months after treatment. The irradiation dose and extent fields were determined by the attending physicians considering various patient factors, such as a performance status, prognosis and presence or absence of adjuvant therapy. The median irradiation dose was 60.4 Gy3.5 (43.6-76.1 Gy3.5) based on the calculation of equivalents of 2 Gy fractions, and the median total number of sensitizer injections was 5 (2-7) times. The median maximum tumor shrinkage was 97.0% and 15 patients (50%) were assessed to have achieved a clinical complete response. The proportion with loco-regional control at 1, 2 and 3 years was 100, 94.7 and 75.4%, respectively, and progression free survival after RT at 1 and 2 years was 59.0 and 24.1%, respectively. KORTUC II exhibited high rates of local tumor control for LABC and LRBC. KORTUC II is expected to be an inexpensive and promising RT method because it is safe and has an excellent radio-sensitizing effect. D.A. Spandidos 2021-11 2021-09-24 /pmc/articles/PMC8506568/ /pubmed/34650808 http://dx.doi.org/10.3892/mco.2021.2388 Text en Copyright: © Shimbo et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Shimbo, Taiju
Nakata, Mio
Yoshioka, Hiroto
Sato, Chikara
Hori, Akihiro
Kimura, Kosei
Iwamoto, Mitsuhiko
Yoshida, Ken
Uesugi, Yasuo
Akiyama, Hironori
Nihei, Keiji
New enzyme-targeting radiosensitizer (KORTUC II) treatment for locally advanced or recurrent breast cancer
title New enzyme-targeting radiosensitizer (KORTUC II) treatment for locally advanced or recurrent breast cancer
title_full New enzyme-targeting radiosensitizer (KORTUC II) treatment for locally advanced or recurrent breast cancer
title_fullStr New enzyme-targeting radiosensitizer (KORTUC II) treatment for locally advanced or recurrent breast cancer
title_full_unstemmed New enzyme-targeting radiosensitizer (KORTUC II) treatment for locally advanced or recurrent breast cancer
title_short New enzyme-targeting radiosensitizer (KORTUC II) treatment for locally advanced or recurrent breast cancer
title_sort new enzyme-targeting radiosensitizer (kortuc ii) treatment for locally advanced or recurrent breast cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506568/
https://www.ncbi.nlm.nih.gov/pubmed/34650808
http://dx.doi.org/10.3892/mco.2021.2388
work_keys_str_mv AT shimbotaiju newenzymetargetingradiosensitizerkortuciitreatmentforlocallyadvancedorrecurrentbreastcancer
AT nakatamio newenzymetargetingradiosensitizerkortuciitreatmentforlocallyadvancedorrecurrentbreastcancer
AT yoshiokahiroto newenzymetargetingradiosensitizerkortuciitreatmentforlocallyadvancedorrecurrentbreastcancer
AT satochikara newenzymetargetingradiosensitizerkortuciitreatmentforlocallyadvancedorrecurrentbreastcancer
AT horiakihiro newenzymetargetingradiosensitizerkortuciitreatmentforlocallyadvancedorrecurrentbreastcancer
AT kimurakosei newenzymetargetingradiosensitizerkortuciitreatmentforlocallyadvancedorrecurrentbreastcancer
AT iwamotomitsuhiko newenzymetargetingradiosensitizerkortuciitreatmentforlocallyadvancedorrecurrentbreastcancer
AT yoshidaken newenzymetargetingradiosensitizerkortuciitreatmentforlocallyadvancedorrecurrentbreastcancer
AT uesugiyasuo newenzymetargetingradiosensitizerkortuciitreatmentforlocallyadvancedorrecurrentbreastcancer
AT akiyamahironori newenzymetargetingradiosensitizerkortuciitreatmentforlocallyadvancedorrecurrentbreastcancer
AT niheikeiji newenzymetargetingradiosensitizerkortuciitreatmentforlocallyadvancedorrecurrentbreastcancer